Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

A simple, 3-factor pre-treatment score (Toranomon Prognostic Score) robustly stratifies progression risk in patients with relapsed/refractory large B-cell lymphoma receiving commercial CAR T-cell therapy: A real-world analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

GYGo YamamotoKKKosei Kageyama

Discussion

Loading...

Member takes

Overview

Real-world analysis shows CAR T-cell therapy improves progression-free survival in large B-cell lymphoma, suggesting key prognostic factors can guide treatment decisions.

Key Points

  • Progression-free survival was significantly influenced by pre-treatment factors in R/R large B-cell lymphoma patients receiving CAR T-cell therapy.
  • Key factors identified through univariate analysis include sensitivity to bridging therapy, elevated LDH and time to relapse.
  • The Toranomon Prognostic Score effectively stratified patients into low, intermediate, and high-risk groups based on their prognosis.
  • Findings emphasize the importance of robust pre-treatment risk stratification in optimizing patient selection for CAR T-cell therapy.

Cite This Study

Yamamoto et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d588https://doi.org/10.1182/blood-2025-1942
View Full Paper
Ask AI
Bookmark
Share